teriparatide
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteoporosis, Postmenopausal
Conditions
Osteoporosis, Postmenopausal
Trial Timeline
Nov 1, 2007 → May 1, 2011
NCT ID
NCT00557310About teriparatide
teriparatide is a approved stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00557310. Target conditions include Osteoporosis, Postmenopausal.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01705587 | Approved | Completed |
| NCT01360424 | Approved | Completed |
| NCT00826228 | Approved | Completed |
| NCT00696644 | Pre-clinical | Completed |
| NCT00535860 | Phase 2 | Completed |
| NCT00577863 | Phase 3 | Completed |
| NCT00557310 | Approved | Completed |
| NCT00259298 | Approved | Completed |
| NCT00191867 | Phase 2 | Completed |
| NCT00191321 | Phase 3 | Completed |
| NCT00532207 | Phase 3 | Completed |
| NCT00191893 | Phase 3 | Completed |
| NCT00191802 | Phase 3 | Completed |
| NCT00532545 | Approved | Completed |
Competing Products
20 competing products in Osteoporosis, Postmenopausal